Notice of intent to list: Mitoxantrone Hydrochloride

Posted Date: 
Wednesday, November 12, 2014

This news update on Mitoxantrone Hydrochloride is brough to you by OEHHA

The California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) intends to list mitoxantrone hydrochloride as known to the State to cause cancer under the Safe Drinking Water and Toxic Enforcement Act of 19861 This action is being proposed under the “Formally Required to Be Labeled or Identified” listing mechanism.

Mitoxantrone hydrochloride has been identified and labeled to communicate a risk of cancer (FDA, 2012) in accordance with formal requirements by the US Food and Drug Administration (FDA). The FDA-approved label indicates that mitoxantrone hydrochloride therapy in patients with multiple sclerosis and in patients with cancer increases the risk of developing secondary acute myeloid leukemia (a type of cancer of the lymphohematopoietic system). NOVANTRONE® is a trade name of mitoxantrone hydrochloride.

OEHHA is requesting comments as to whether this chemical meets the criteria set forth in the Proposition 65 regulations for listings via the formally required to be labeled or identified mechanism (Section 25902). Because these are ministerial listings, comments should be limited to whether FDA requires that mitoxantrone hydrochloride be labeled to communicate a risk of cancer or tumors. OEHHA cannot consider scientific arguments concerning the weight or quality of the evidence considered by FDA when it established the labeling requirement and will not respond to such comments if they are submitted.

For more information on Mitoxantrone Hydrochloride please visit the OEHHA link above. Please contact Nexreg for Prop 65 Compliance


We help US and International clients prepare their chemical packaging labeling for marketing success in Canada. It has been my pleasure to work with Nexreg for the last 2 years on many domestic and international jobs. They have provided my company, and my clients, with CCCR determination and other product assessments in a timely, professional and forthright manner. Their employees, such as James Dayus, have been proactive, professional and personable. I trust them to talk directly to my clients and they have never let me down on professional document completion or deadlines. They are great to work with and I wholeheartedly endorse their work.
Stephen Morton, Tempest Studios